Pharsight

Zeposia is owned by Celgene Intl.

Zeposia contains Ozanimod Hydrochloride.

Zeposia has a total of 4 drug patents out of which 0 drug patents have expired.

Zeposia was authorised for market use on 25 March, 2020.

Zeposia is available in capsule;oral dosage forms.

Zeposia can be used as treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, indicated for the treatment of moderately to severely active ulcerative colitis.

Drug patent challenges can be filed against Zeposia from March, 2024.

The generics of Zeposia are possible to be released after 15 November, 2030.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481573	CELGENE INTL	Modulators of sphingosine phosphate receptors	May, 2029 (6 years from now)
US8796318	CELGENE INTL	Modulators of sphingosine phosphate receptors	May, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9382217	CELGENE INTL	Modulators of sphingosine phosphate receptors	May, 2029 (6 years from now)
US10239846	CELGENE INTL	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis	Nov, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	May 27, 2024
New Chemical Entity Exclusivity (NCE)	Mar 25, 2025

Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient

NCE-1 date: March, 2024

Market Authorisation Date: 25 March, 2020

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the treatment of moderately to severely active ulcerative colitis

Dosage: CAPSULE;ORAL